Strong Q3 Results Drive Guardant’s Stock 15% Higher In 20 Days

Guardant Health (NASDAQ:GH) offers non-invasive cancer diagnosis tests and is based out of the U.S. The company has seen its stock rally 15% since its Q3 results were announced. The company reported strong results in Q3 with sales growth coming in at $61 Mil – a 181% jump year-on-year. Earnings loss for the company also narrowed to -$0.14 per share – much better than the consensus estimate of -$0.37. Additionally, the company raised its revenue guidance for full-year 2019 to the $202-$207 Mil range from $180-$190 Mil.

We step back from these recent swings to review Guardant Health’s performance over the last few years, as a context for what might come next. Our Interactive dashboard – Why has Guardant Health rallied by 15% in the last 20 days?, reviews the near term reasons and the big picture.

 

The context for the last few years:

A closer look At Guardant Health’s Total Revenues over the last few years and the outlook.

Total Revenues for Guardant Health substantially increased from $49.8 Mil in 2017 to $90.6 Mil in 2018; an increase of 81.9%. (Increase is on account of higher volumes of Guardant360 Oncology Test)

This compares with Total Revenues growth of 97.4% in 2017. (Increase is on account of higher volumes of Guardant360 Oncology Test) We expect Total Revenues growth to be 127.3% in 2019 (on account of approval for Liquid Biopsy Testing).

 

A closer look At Guardant Health’s Total Expenses over the last few years and the outlook

Total Expense for Guardant Health substantially increased from $133 Mil in 2017 to $175 Mil in 2018; an increase of 31.4%.

This compares with Total Expense growth of 86.4% in 2017. We expect Total Expense growth to be 66.2% in 2019.

 

How does Guardant Health’s Revenue Growth compare with rivals?

For more information on how Guardant Health’s revenue growth compares with Alnylam Pharmaceuticals, Alkermes and Agios Pharmaceuticals, view our interactive dashboard analysis.

 

How has Guardant Health’s EBT trended?

LBT for Guardant Health increased marginally by 1.21% from $83.2 Mil in 2017 to $84.2 Mil in 2018.

We expect LBT to increase by 0.5% to $84.2 Mil in 2019.

 

How has Guardant Health’s Net Income and EPS trended?

For more details about Guardant Health’s Net Income and EPS, view our interactive dashboard analysis.

 

What’s behind Trefis? See How It’s Powering New Collaboration and What-Ifs For CFOs and Finance TeamsProduct, R&D, and Marketing Teams More Trefis Data Like our charts? Explore example interactive dashboards and create your own

Led by MIT engineers and Wall Street analysts, Trefis (through its dashboards platform dashboards.trefis.com) helps you understand how a company's products, that you tou...